SlideShare a Scribd company logo
1 of 6
Download to read offline
IDEAL (Incremental Decrease in
Endpoints through Aggressive Lipid
Lowering)
IDEAL (Incremental Decrease in Endpoints through
Aggressive Lipid Lowering)
T Pedersen (Ullevål University Hospital, Oslo, Norway)
American Heart Association 2005 Scientific Sessions


• Background:
    IDEAL is a "lower-is-better" investigation comparing high-dose atorvastatin
    (80 mg) with simvastatin 20 mg, a dose widely used in clinical practice
• A prospective, randomized, open-label, blinded-end-point evaluation trial
• Population:
    8888 patients aged 80 years or younger with a history of acute MI
• Primary outcome:
    Composite of coronary death, nonfatal MI, or cardiac arrest with
    resuscitation
IDEAL: Results

• At a five-year follow-up mean LDL-C was 80.0 mg/dL in atorvastatin patients
  and 99.8 mg/dL in simvastatin patients
• There was no statistical difference in the incidence of the primary end point
  between the two arms

Primary outcomea
Outcome (%)                           Simvastatin (n=4449)             Atorvastatin (n=4439)   Hazard ratio
                                                                                               (95% CI)


Major coronary eventb                 10.4                             9.3                     0.89 (0.78–1.01)

CHD death                             4.0                              3.9                     0.99 (0.80–1.22)

Nonfatal MI                           7.2                              6.0                     0.83 (0.71–0.98)

Cardiac arrest with resuscitation     0.2                              0.2                     NA


a. At a median of 4.8 years
b. Coronary death, nonfatal MI, or cardiac arrest with resuscitation
IDEAL: Results

• The composite secondary end point of a major CV eventa was significantly
  reduced in patients treated with atorvastatin
Secondary outcomesb
Outcome (%)                           Simvastatin (n=4449)   Atorvastatin (n=4439)   Hazard ratio
                                                                                     (95% CI)


Any CHD event                         23.8                   20.2                    0.84 (0.76–0.91)

Coronary revascularization            16.7                   13.0                    0.77 (0.69–0.86)

Hospitalization for unstable angina   5.3                    4.4                     0.83 (0.69–1.01)

Fatal or nonfatal stroke              3.9                    3.4                     0.87 (0.70–1.08)

Major CV event                        13.7                   12.0                    0.87 (0.78–0.98)

Any CV event                          30.8                   26.5                    0.84 (0.78–0.91)


a. Major coronary events and stroke
b. At a median of 4.8 years
IDEAL: Commentary*

"Nothing magical seems to happen here that would make us shift our focus away
from LDL-lowering effects. The important point is to lower LDL cholesterol to
sufficiently low levels to provide incremental benefit."

                                                                                            - Dr James de Lemos


"Saying that it is difficult is not saying that we shouldn't try. . . . What the guidelines
are really telling clinicians is to get the LDL cholesterol down as low as you safely
can."

                                                                                                - Dr Steven Nissen




 *All comments from IDEAL: Intensive lipid lowering after acute MI did not reduce the risk of major
 coronary events (http://www.theheart.org/article/598723.do)
Become a member of http://www.theheart.org
    Become a fan on Facebook: http://www.facebook.com/theheartorg
          Follow us on Twitter: http://www.twitter.com/theheartorg

theheart.org is the leading online source of independent cardiology news.
We are the top provider of news and opinions for over 100 000 physicians.

More Related Content

Similar to IDEAL trial - Summary & Results

CHAMPION trial - Summary & Results
CHAMPION trial - Summary & Results CHAMPION trial - Summary & Results
CHAMPION trial - Summary & Results theheart.org
 
Future of site stable to unstable
Future of site stable to unstableFuture of site stable to unstable
Future of site stable to unstableoptimacardio
 
Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...
Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...
Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...Cristiano Amarelli
 
Prasugrel Compared With Clopidogrel In Patients Stemi
Prasugrel Compared With Clopidogrel In Patients StemiPrasugrel Compared With Clopidogrel In Patients Stemi
Prasugrel Compared With Clopidogrel In Patients Stemihospital
 
Impact of previous stenting on the outcome of (2)
Impact of previous stenting on the outcome of (2)Impact of previous stenting on the outcome of (2)
Impact of previous stenting on the outcome of (2)escts2012
 
ARTESIA tial - use of apixaban in subclinical atrial fibrillation
ARTESIA tial - use of apixaban in subclinical atrial fibrillationARTESIA tial - use of apixaban in subclinical atrial fibrillation
ARTESIA tial - use of apixaban in subclinical atrial fibrillationAvishkar Agrawal
 
TRACER trial - Summary & Results
TRACER trial - Summary & ResultsTRACER trial - Summary & Results
TRACER trial - Summary & Resultstheheart.org
 
ONTARGET trial - Summary & Results with Ramipril Global Endpoint
ONTARGET trial - Summary & Results with Ramipril Global EndpointONTARGET trial - Summary & Results with Ramipril Global Endpoint
ONTARGET trial - Summary & Results with Ramipril Global Endpointtheheart.org
 
Pletaal (cilostazol) utk dokter.ppt (a)
Pletaal (cilostazol) utk dokter.ppt (a)Pletaal (cilostazol) utk dokter.ppt (a)
Pletaal (cilostazol) utk dokter.ppt (a)peyekiwak287
 
PRODIGY trial - Summary & Results
PRODIGY trial - Summary & ResultsPRODIGY trial - Summary & Results
PRODIGY trial - Summary & Resultstheheart.org
 
G Lipid Lowering In Ckd
G Lipid Lowering In CkdG Lipid Lowering In Ckd
G Lipid Lowering In Ckdconall100
 
PLATO (Platelet Inhibition and Patient Outcomes)
PLATO (Platelet Inhibition and Patient Outcomes)PLATO (Platelet Inhibition and Patient Outcomes)
PLATO (Platelet Inhibition and Patient Outcomes)theheart.org
 

Similar to IDEAL trial - Summary & Results (20)

AHA: LBCT
AHA: LBCTAHA: LBCT
AHA: LBCT
 
Aha lbct
Aha lbctAha lbct
Aha lbct
 
Randil
RandilRandil
Randil
 
CHAMPION trial - Summary & Results
CHAMPION trial - Summary & Results CHAMPION trial - Summary & Results
CHAMPION trial - Summary & Results
 
HEART2D TRIAL
HEART2D TRIALHEART2D TRIAL
HEART2D TRIAL
 
Future of site stable to unstable
Future of site stable to unstableFuture of site stable to unstable
Future of site stable to unstable
 
Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...
Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...
Amarelli 313 Transplantation Ii Early Graft Failure After Heart Transplant Le...
 
Prasugrel Compared With Clopidogrel In Patients Stemi
Prasugrel Compared With Clopidogrel In Patients StemiPrasugrel Compared With Clopidogrel In Patients Stemi
Prasugrel Compared With Clopidogrel In Patients Stemi
 
Impact of previous stenting on the outcome of (2)
Impact of previous stenting on the outcome of (2)Impact of previous stenting on the outcome of (2)
Impact of previous stenting on the outcome of (2)
 
Hyvet Slide Set
Hyvet Slide SetHyvet Slide Set
Hyvet Slide Set
 
ARTESIA tial - use of apixaban in subclinical atrial fibrillation
ARTESIA tial - use of apixaban in subclinical atrial fibrillationARTESIA tial - use of apixaban in subclinical atrial fibrillation
ARTESIA tial - use of apixaban in subclinical atrial fibrillation
 
TRACER trial - Summary & Results
TRACER trial - Summary & ResultsTRACER trial - Summary & Results
TRACER trial - Summary & Results
 
ONTARGET trial - Summary & Results with Ramipril Global Endpoint
ONTARGET trial - Summary & Results with Ramipril Global EndpointONTARGET trial - Summary & Results with Ramipril Global Endpoint
ONTARGET trial - Summary & Results with Ramipril Global Endpoint
 
Pletaal (cilostazol) utk dokter.ppt (a)
Pletaal (cilostazol) utk dokter.ppt (a)Pletaal (cilostazol) utk dokter.ppt (a)
Pletaal (cilostazol) utk dokter.ppt (a)
 
PRODIGY trial - Summary & Results
PRODIGY trial - Summary & ResultsPRODIGY trial - Summary & Results
PRODIGY trial - Summary & Results
 
G Lipid Lowering In Ckd
G Lipid Lowering In CkdG Lipid Lowering In Ckd
G Lipid Lowering In Ckd
 
PLATO (Platelet Inhibition and Patient Outcomes)
PLATO (Platelet Inhibition and Patient Outcomes)PLATO (Platelet Inhibition and Patient Outcomes)
PLATO (Platelet Inhibition and Patient Outcomes)
 
18 3-2011
18 3-201118 3-2011
18 3-2011
 
Aversano
AversanoAversano
Aversano
 
GUIAS AMERICANAS DE HIPERTENSION ARTERIAL 2017
GUIAS AMERICANAS DE HIPERTENSION ARTERIAL 2017GUIAS AMERICANAS DE HIPERTENSION ARTERIAL 2017
GUIAS AMERICANAS DE HIPERTENSION ARTERIAL 2017
 

More from theheart.org

ESC 2012 research highlights: A slideshow presentation
ESC 2012 research highlights: A slideshow presentationESC 2012 research highlights: A slideshow presentation
ESC 2012 research highlights: A slideshow presentationtheheart.org
 
AHA 2012 Research Highlights
AHA 2012 Research HighlightsAHA 2012 Research Highlights
AHA 2012 Research Highlightstheheart.org
 
AHA 2010 research highlights: A slideshow presentation
AHA 2010 research highlights: A slideshow presentation AHA 2010 research highlights: A slideshow presentation
AHA 2010 research highlights: A slideshow presentation theheart.org
 
TCT 2010 research highlights: A slideshow presentation
TCT 2010 research highlights: A slideshow presentation TCT 2010 research highlights: A slideshow presentation
TCT 2010 research highlights: A slideshow presentation theheart.org
 
ESC 2010 Research Highlights : A slideshow presentation
ESC 2010 Research Highlights : A slideshow presentationESC 2010 Research Highlights : A slideshow presentation
ESC 2010 Research Highlights : A slideshow presentationtheheart.org
 
OASIS-6 trial - Summary & Results at ACC
OASIS-6 trial - Summary & Results at ACCOASIS-6 trial - Summary & Results at ACC
OASIS-6 trial - Summary & Results at ACCtheheart.org
 
PURE trial - Summary & Results
PURE trial - Summary & ResultsPURE trial - Summary & Results
PURE trial - Summary & Resultstheheart.org
 
ACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & ResultsACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & Resultstheheart.org
 
RIVAL trial - Summary & Results
RIVAL trial - Summary & ResultsRIVAL trial - Summary & Results
RIVAL trial - Summary & Resultstheheart.org
 
ACT trial - Summary & Results
ACT trial - Summary & ResultsACT trial - Summary & Results
ACT trial - Summary & Resultstheheart.org
 
P-OM3 trial - Summary & Results
P-OM3 trial - Summary & ResultsP-OM3 trial - Summary & Results
P-OM3 trial - Summary & Resultstheheart.org
 
SHIFT trial - Summary & Results
SHIFT trial - Summary & ResultsSHIFT trial - Summary & Results
SHIFT trial - Summary & Resultstheheart.org
 
PROTECT-AF trial - Summary & Results
PROTECT-AF trial - Summary & ResultsPROTECT-AF trial - Summary & Results
PROTECT-AF trial - Summary & Resultstheheart.org
 
PRELUDE trial - Summary & Results
PRELUDE trial - Summary & ResultsPRELUDE trial - Summary & Results
PRELUDE trial - Summary & Resultstheheart.org
 
ALTITUDE trial - Summary & Results
ALTITUDE trial - Summary & ResultsALTITUDE trial - Summary & Results
ALTITUDE trial - Summary & Resultstheheart.org
 
PRECOMBAT trial - Summary & Results
PRECOMBAT trial - Summary & ResultsPRECOMBAT trial - Summary & Results
PRECOMBAT trial - Summary & Resultstheheart.org
 
OSCAR trial - Summary & Results
OSCAR trial - Summary & ResultsOSCAR trial - Summary & Results
OSCAR trial - Summary & Resultstheheart.org
 
MAGELLAN trial - Summary & Results
MAGELLAN trial - Summary & ResultsMAGELLAN trial - Summary & Results
MAGELLAN trial - Summary & Resultstheheart.org
 
EVEREST trial - Summary & Results
EVEREST trial - Summary & ResultsEVEREST trial - Summary & Results
EVEREST trial - Summary & Resultstheheart.org
 
CARE-HF trial - Summary & Results
CARE-HF trial - Summary & ResultsCARE-HF trial - Summary & Results
CARE-HF trial - Summary & Resultstheheart.org
 

More from theheart.org (20)

ESC 2012 research highlights: A slideshow presentation
ESC 2012 research highlights: A slideshow presentationESC 2012 research highlights: A slideshow presentation
ESC 2012 research highlights: A slideshow presentation
 
AHA 2012 Research Highlights
AHA 2012 Research HighlightsAHA 2012 Research Highlights
AHA 2012 Research Highlights
 
AHA 2010 research highlights: A slideshow presentation
AHA 2010 research highlights: A slideshow presentation AHA 2010 research highlights: A slideshow presentation
AHA 2010 research highlights: A slideshow presentation
 
TCT 2010 research highlights: A slideshow presentation
TCT 2010 research highlights: A slideshow presentation TCT 2010 research highlights: A slideshow presentation
TCT 2010 research highlights: A slideshow presentation
 
ESC 2010 Research Highlights : A slideshow presentation
ESC 2010 Research Highlights : A slideshow presentationESC 2010 Research Highlights : A slideshow presentation
ESC 2010 Research Highlights : A slideshow presentation
 
OASIS-6 trial - Summary & Results at ACC
OASIS-6 trial - Summary & Results at ACCOASIS-6 trial - Summary & Results at ACC
OASIS-6 trial - Summary & Results at ACC
 
PURE trial - Summary & Results
PURE trial - Summary & ResultsPURE trial - Summary & Results
PURE trial - Summary & Results
 
ACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & ResultsACCORD BP trial - Summary & Results
ACCORD BP trial - Summary & Results
 
RIVAL trial - Summary & Results
RIVAL trial - Summary & ResultsRIVAL trial - Summary & Results
RIVAL trial - Summary & Results
 
ACT trial - Summary & Results
ACT trial - Summary & ResultsACT trial - Summary & Results
ACT trial - Summary & Results
 
P-OM3 trial - Summary & Results
P-OM3 trial - Summary & ResultsP-OM3 trial - Summary & Results
P-OM3 trial - Summary & Results
 
SHIFT trial - Summary & Results
SHIFT trial - Summary & ResultsSHIFT trial - Summary & Results
SHIFT trial - Summary & Results
 
PROTECT-AF trial - Summary & Results
PROTECT-AF trial - Summary & ResultsPROTECT-AF trial - Summary & Results
PROTECT-AF trial - Summary & Results
 
PRELUDE trial - Summary & Results
PRELUDE trial - Summary & ResultsPRELUDE trial - Summary & Results
PRELUDE trial - Summary & Results
 
ALTITUDE trial - Summary & Results
ALTITUDE trial - Summary & ResultsALTITUDE trial - Summary & Results
ALTITUDE trial - Summary & Results
 
PRECOMBAT trial - Summary & Results
PRECOMBAT trial - Summary & ResultsPRECOMBAT trial - Summary & Results
PRECOMBAT trial - Summary & Results
 
OSCAR trial - Summary & Results
OSCAR trial - Summary & ResultsOSCAR trial - Summary & Results
OSCAR trial - Summary & Results
 
MAGELLAN trial - Summary & Results
MAGELLAN trial - Summary & ResultsMAGELLAN trial - Summary & Results
MAGELLAN trial - Summary & Results
 
EVEREST trial - Summary & Results
EVEREST trial - Summary & ResultsEVEREST trial - Summary & Results
EVEREST trial - Summary & Results
 
CARE-HF trial - Summary & Results
CARE-HF trial - Summary & ResultsCARE-HF trial - Summary & Results
CARE-HF trial - Summary & Results
 

Recently uploaded

Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsPradnya Wadekar
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptxtusharchokshi1
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfMayuriGamit2
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxVeereshDemashetti
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionZeinabEmad3
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...Genesis Institute of Pharmacy, Radhanagari.
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhanthesalberry
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, PDr.Shalu Jain
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfNetHelix
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...JakeMatthews12
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfHongBiThi1
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersSai Sailesh Kumar Goothy
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUKanhu Charan
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......anupamdas2143
 
Spinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxSpinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxsiddharthroy26587
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedSBL DIGITAL
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Dr. Dheeraj Kumar
 

Recently uploaded (20)

Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractions
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptx
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
 
Oral disorders .pptx
Oral disorders .pptxOral disorders .pptx
Oral disorders .pptx
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptx
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), Addiction
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhan
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, P
 
Problems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdfProblems associated with the production of recombinant protein.pdf
Problems associated with the production of recombinant protein.pdf
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
 
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disorders
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......
 
Spinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxSpinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptx
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limited
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
 

IDEAL trial - Summary & Results

  • 1. IDEAL (Incremental Decrease in Endpoints through Aggressive Lipid Lowering)
  • 2. IDEAL (Incremental Decrease in Endpoints through Aggressive Lipid Lowering) T Pedersen (Ullevål University Hospital, Oslo, Norway) American Heart Association 2005 Scientific Sessions • Background: IDEAL is a "lower-is-better" investigation comparing high-dose atorvastatin (80 mg) with simvastatin 20 mg, a dose widely used in clinical practice • A prospective, randomized, open-label, blinded-end-point evaluation trial • Population: 8888 patients aged 80 years or younger with a history of acute MI • Primary outcome: Composite of coronary death, nonfatal MI, or cardiac arrest with resuscitation
  • 3. IDEAL: Results • At a five-year follow-up mean LDL-C was 80.0 mg/dL in atorvastatin patients and 99.8 mg/dL in simvastatin patients • There was no statistical difference in the incidence of the primary end point between the two arms Primary outcomea Outcome (%) Simvastatin (n=4449) Atorvastatin (n=4439) Hazard ratio (95% CI) Major coronary eventb 10.4 9.3 0.89 (0.78–1.01) CHD death 4.0 3.9 0.99 (0.80–1.22) Nonfatal MI 7.2 6.0 0.83 (0.71–0.98) Cardiac arrest with resuscitation 0.2 0.2 NA a. At a median of 4.8 years b. Coronary death, nonfatal MI, or cardiac arrest with resuscitation
  • 4. IDEAL: Results • The composite secondary end point of a major CV eventa was significantly reduced in patients treated with atorvastatin Secondary outcomesb Outcome (%) Simvastatin (n=4449) Atorvastatin (n=4439) Hazard ratio (95% CI) Any CHD event 23.8 20.2 0.84 (0.76–0.91) Coronary revascularization 16.7 13.0 0.77 (0.69–0.86) Hospitalization for unstable angina 5.3 4.4 0.83 (0.69–1.01) Fatal or nonfatal stroke 3.9 3.4 0.87 (0.70–1.08) Major CV event 13.7 12.0 0.87 (0.78–0.98) Any CV event 30.8 26.5 0.84 (0.78–0.91) a. Major coronary events and stroke b. At a median of 4.8 years
  • 5. IDEAL: Commentary* "Nothing magical seems to happen here that would make us shift our focus away from LDL-lowering effects. The important point is to lower LDL cholesterol to sufficiently low levels to provide incremental benefit." - Dr James de Lemos "Saying that it is difficult is not saying that we shouldn't try. . . . What the guidelines are really telling clinicians is to get the LDL cholesterol down as low as you safely can." - Dr Steven Nissen *All comments from IDEAL: Intensive lipid lowering after acute MI did not reduce the risk of major coronary events (http://www.theheart.org/article/598723.do)
  • 6. Become a member of http://www.theheart.org Become a fan on Facebook: http://www.facebook.com/theheartorg Follow us on Twitter: http://www.twitter.com/theheartorg theheart.org is the leading online source of independent cardiology news. We are the top provider of news and opinions for over 100 000 physicians.